For citations:

Plavinskii S.L., Shabalkin P.I. Clinical and economic analysis of Degarelix (Firmagon) in treatment of patients with advanced hormone-dependent prostate cancer. Malignant tumours. 2014;(1):32-38. (In Russ.) https://doi.org/10.18027/2224-5057-2014-1-32-38